Amy Maher

Launched the antibody drug conjugate Tivdak for cervical cancer to gynecologic and medical oncologists in Nebraska, Iowa, South Dakota, North Dakota, and Minnesota. Strategize coverage of five states with a nurse educator to implement in-services on all new patient starts.

Accomplishments:

• Top 5 rank during launch
• Received "Linker Award" for best team collaboration in division
• Led first Genmab/Seagen co-promotion calls for entire nation
• Selected to lead division during Prizer transition for all operational procedures

Launch and promotion of anti-body drug conjugate Enhertu for breast and gastric cancer to medical oncologists. Partnerships with Clinical Nurse Educator and cross-promotional colleagues including field reimbursement manager and regional account manager

• 125% launch goal achievement
• Selected to represent field sales on global company culture committee
• Field representative for 'Best Practices' committee
• 2019 Division MVP

Launched PARP inhibitor Rubraca in ovarian cancer. Call points included medical and gynecological oncologists in Nebraska and Kansas. Worked closely with Nurse Educator, Field Access Coordinator and Regional Account Director to pull through business goals in territory

• Finished 2018 ranked #3 in the nation at 127% to plan
• Received the 2018 Clovis Oncology Apex award for volume and percentage growth
• Largest jump in 'percent to goal' in nation in 2018
• Chosen as a national lead in structuring the inaugural sample program at Clovis
• Completed 2017 over 100% to plan

Promotion of oral targeted therapy Zelboraf for BRAF+ metastatic melanoma to academic and medical oncologists in Nebraska and Iowa. Promotion of small molecule inhibitor, Erivedge, to oncologists, dermatologists and MOHs surgeons across Nebraska and Iowa for treatment of basal cell carcinoma. Partnered with 12 additional Genentech representatives across Nebraska and Iowa to maximize visibility in clinics and academic centers

• 2014 received the first West Region award for Genentech's Skin Franchise for sales and partnership achievement
• Regional lead for Genentech's national nursing recognition program
• Zelboraf product team
• Ops team
• BFRM Advisory Board
• Oncology mentee to new-to-oncology representatives within West Region

Promotion of oral targeted therapy, Afinitor, for treatment of advanced pancreatic neuroendocrine tumors and renal cell carcinoma to community and academic oncologists in Nebraska and South Dakota. Promotion of intramuscular injection, Sandostatin LAR for treatment of carcinoid syndrome related to metastatic carcinoid tumors

• Developed lead regional pancreatic surgeon as Novartis speaker within first four months in territory
• Aided in the development of Novartis' company wide specialty pharmacy preceptorship

Promotion of metastatic breast cancer injectable chemotherapy Halaven and Dacogen for myelodysplastic syndrome to medical oncologists and hematologists. Also responsible for the promotion of the anti-emetic injectable Aloxi. Initiated and managed clinic and hospital contracts for Aloxi to pharmacists and other ancillary staff within clinics

• #1 in sales 2013
• Increased breast cancer sales from 55% to 120% of goal
• Grew hematology sales from 63% to 205% of goal in one year
• 2009 promoted to Senior Sales Representative
• Achiphex Advisory Board
• 2007 Nightingale winner-top 12 representatives in Nation
• 2006 Nightingale winner-top 12 representatives in Nation
• 2005 & 2006 Pinnacle (top District) award winner
• 2006 District HHC winner

Marketing of high-risk pregnancy services and pharmaceuticals to all obstetric physicians, perinatologists, hospitals and large insurance plans in Nebraska and Iowa.

• Negotiated placement of preterm labor services on hospital contracts
• Negotiated insurance contracts with Medical Directors of major insurance plans in Nebraska and Iowa
• Established purchase order agreements in top 3 hospitals in Nebraska & Iowa
• Consistently achieved 100% of quota
• Doubled insurance coverage of core services in one year

Promotion of 6 products ranging from analgesic, anti-infective, women's health and wound care. Marketed products to Primary Care, Internal Medicine, Urology, Rheumatology, Surgeons, and Dermatology.

• 2001 top 10 regional sales ranking
• #1 in region for share growth versus anticholinergic competitor
• 2001 rep of the cycle
• Grew market share of Regranex over 200% in 2001